CMS has tools at its disposal to protect Part D beneficiaries from insurance policies the drug industry lobby says could limit patients’ ability to benefit from lower prices negotiated under the Inflation Reduction Act (IRA), according to a report from the Alliance of Aging Research and Manatt. The Alliance and Manatt suggest CMS set general minimum standards for plans participating in Part D, including regulating which drugs are put on plans’ specialty tiers, and improve the beneficiary appeals process. A...